Department of Biochemistry, School of Medicine and Immune-Network Pioneer Research Center, Dong-A University, 32, Daesingongwon-ro, Seo-gu, Busan 602-714, Korea.
Mar Drugs. 2014 Jan 28;12(2):851-70. doi: 10.3390/md12020851.
Fucoidan is a fucose-containing sulfated polysaccharide derived from brown seaweeds, crude extracts of which are commercially available as nutritional supplements. Recent studies have demonstrated antiproliferative, antiangiogenic, and anticancer properties of fucoidan in vitro. Accordingly, the anticancer effects of fucoidan have been shown to vary depending on its structure, while it can target multiple receptors or signaling molecules in various cell types, including tumor cells and immune cells. Low toxicity and the in vitro effects of fucoidan mentioned above make it a suitable agent for cancer prevention or treatment. However, preclinical development of natural marine products requires in vivo examination of purified compounds in animal tumor models. This review discusses the effects of systemic and local administration of fucoidan on tumor growth, angiogenesis, and immune reaction and whether in vivo and in vitro results are likely applicable to the development of fucoidan as a marine anticancer drug.
岩藻聚糖是一种来源于褐藻的含岩藻糖的硫酸多糖,其粗提取物可作为营养补充剂在商业上买到。最近的研究表明岩藻聚糖在体外具有抗增殖、抗血管生成和抗癌特性。因此,岩藻聚糖的抗癌作用被证明与其结构有关,而它可以针对包括肿瘤细胞和免疫细胞在内的各种细胞类型中的多个受体或信号分子。低毒性和上述岩藻聚糖的体外作用使其成为预防或治疗癌症的合适药物。然而,天然海洋产品的临床前开发需要在动物肿瘤模型中对纯化化合物进行体内检查。这篇综述讨论了全身性和局部给予岩藻聚糖对肿瘤生长、血管生成和免疫反应的影响,以及体内和体外结果是否可能适用于将岩藻聚糖开发为海洋抗癌药物。